
1. med sante trop. 2013 jul-sep;23(3):313-9. doi: 10.1684/mst.2013.0229.

[efficacy safety antimalarial combinations treatment uncomplicated 
malaria children bangui, central african republic].

[article french]

nambei ws(1), lango yaya e, pounguinza s, achonduh o, bogon a, lengande r, evehe 
ms, ekollo mbange ah, mbacham w.

author information: 
(1)unité d'immunologie, de biologie moléculaire et de biochimie, laboratoire
national de biologie et santé publique et de la population, unité de
chimiorésistance du paludisme, 1426 bangui, république centrafricaine.

objective: aim study evaluate efficacy safety three
anti-malarial combinations--artemether-lumefantrine (a-l),
amodiaquine-sulfadoxine-pyrimethamine (aq-sp), artesunate-amodiaquine
(aq-as)--in treatment uncomplicated malaria children younger 5
years bangui, central african republic.
methodology: study included 186 children aged 6-59 months uncomplicated
falciparum malaria treated bédé combattant hospital july
through october 2010: 63 randomized receive a-l, 63 aq-sp, 60 aq-as.
clinical outcome classified according criteria early treatment
failure (etf), late clinical failure (lcf), late parasitological failure (lpf),
or adequate clinical parasitological response (acpr). occurrence of
mutations pfcrt, pfmdr-1, dhfr dhps genes studied pcr-rflp.
results: pcr correction, acpr d28 100% a-l, 96.55% aq-sp,
and 100% aq-as, significant difference three combinations
(p = 0.36). 2 cases treatment failure aq-sp associated with
mutations following resistance markers: pfcrt 76t, pfmdri 86y, dhfr 108n, 
and dhps a437. significant difference reduction anemia,
fever (p = 0.87), parasitemia (p = 0.63) three combinations.
conclusion: study demonstrates artemisinin-based combinations still
effective tolerated treatment uncomplicated malaria children
younger 5 years bangui. treatment failures due new infections and
mutations resistance markers.

doi: 10.1684/mst.2013.0229 
pmid: 24122669  [indexed medline]

